ReviewCureus2026
Use of Artificial Intelligence for the Early Detection and Prediction of Alzheimer's Disease.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder and is a leading cause of dementia. Early detection of disease pathology and prediction of its progression from mild cognitive impairment to AD dementia has important implications in clinical practice and care planning. Current diagnostic methods largely depend on post-symptomatic clinical evaluations or invasive biomarker testing which restricts widespread adoption. This review explores six primary studies utilizing artificial intelligence techniques, specifically machine learning and deep learning algorithms trained on multimodal datasets. Studies were identified through a search of the PubMed database using outlined Medical Subject Headings (MeSH) and text-word terms, and filtered for clinical trials or randomized controlled trials. Models integrating neuroimaging, CSF biomarkers, neuropsychological assessments, and physiological signals achieved high diagnostic and predictive accuracies, surpassing traditional statistical methods. Interpretability tools improved transparency and bridged the gap between model outputs and known AD pathophysiological mechanisms. Despite significant advancements, limitations including small sample sizes, geographical and ethnic homogeneity, limited external validation, and lack of longitudinal validation persist. Future research should aim to use large-scale, multi-center, longitudinal trials to increase generalizability and build clinical trust before widespread adoption. Overall, AI shows strong potential and promise as a clinical decision support tool for early detection and predictive modeling of Alzheimer's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.